Premium
Synergistic anticancer effects of different combinations of He+O 2 plasma jet and doxorubicin on A375 melanoma cells
Author(s) -
Zhang Hao,
Xu Shengduo,
Zhang Jishen,
Li Bing,
Liu Dingxin,
Guo Li,
Liu Zhijie,
Xu Dehui
Publication year - 2021
Publication title -
plasma processes and polymers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.644
H-Index - 74
eISSN - 1612-8869
pISSN - 1612-8850
DOI - 10.1002/ppap.202000239
Subject(s) - doxorubicin , pharmacology , plasma medicine , melanoma , jet (fluid) , anticancer drug , adjuvant , atmospheric pressure plasma , chemistry , drug , cancer research , plasma , medicine , chemotherapy , oncology , physics , quantum mechanics , thermodynamics
Cold atmospheric plasma technology is expected to become an option for adjuvant therapy in cancer due to its promising anticancer effect. Here, we evaluated the effects of different combinations of He+O 2 plasma jet and clinical anticancer drug, doxorubicin, on A375 melanoma cells in vitro. The results show that the synergistic anticancer effect of plasma jet and doxorubicin is dependent on the manner of their combination. Although doxorubicin does not affect plasma jet‐induced exogenous oxidative stress in A375 cells, the synergistic anticancer effect of continuous doxorubicin treatment with subsequent plasma jet treatment is significantly better than that of simultaneous continuous doxorubicin and plasma jet treatment. It is proposed that plasma jet interventions may create transitory therapeutic windows for continuous chemotherapy. Our results will help to optimize therapeutic approaches that include combinations of anticancer drugs and plasma for future clinical applications.